Sutro Biopharma, Inc. filed a current report on August 12, 2026, announcing its financial results for the quarter ended June 30, 2026, and disclosing an updated corporate presentation under Regulation FD.

Key Highlights

  • Reporting period: Financial results cover the quarter ended June 30, 2026.
  • Press release attached: A press release announcing quarterly financial results is included as Exhibit 99.1, dated August 12, 2026.
  • Corporate presentation updated: An updated corporate presentation was disclosed on August 12, 2026, and is attached as Exhibit 99.2.
  • Signed by CFO: The filing was signed by Gregory Chow, Chief Financial Officer of Sutro Biopharma, Inc.
  • Exchange listing: Sutro Biopharma common stock, $0.001 par value, trades on NASDAQ:STRO on The Nasdaq Global Market.

Sutro Biopharma Discloses Second Quarter 2026 Operating Results and Updated Presentation

According to the filing, Sutro Biopharma, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 111 Oyster Point Blvd, South San Francisco, California 94080, issued a press release on August 12, 2026, announcing financial results for the quarter ended June 30, 2026. That press release is furnished as Exhibit 99.1 and is described in Item 2.02 of the report, which covers results of operations and financial condition. The filing notes that this information "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Under Item 7.01, the company disclosed that it would be making available an updated corporate presentation on the same date. This presentation is attached as Exhibit 99.2. As with the press release, the filing states that the Regulation FD disclosure "shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act" and is not incorporated by reference into other filings except as expressly set forth. The filing was signed by Gregory Chow in his capacity as Chief Financial Officer, indicating authorization on behalf of the registrant.

What Was Disclosed

Sutro Biopharma filed a current report on August 12, 2026, furnishing its second quarter 2026 financial results via an attached press release and disclosing an updated corporate presentation under Regulation FD. Both exhibits are furnished rather than filed under the Exchange Act.